SAN DIEGO, Jan. 2, 2024 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced it has completed enrollment in the third cohort…

NEW YORK, Jan. 2, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LivePerson, Inc. (NASDAQ: LPSN) between May 10, 2022 and March 16, 2023, both dates inclusive (the “Class Period”), of the important January 30, 2024 lead…

HACKENSACK, N.J., Jan. 2, 2024 /PRNewswire/ — “Who picks up a call at 11:30 at night,” quips 37-year-old Teaneck resident Jose Vasquez, who almost didn’t answer his cell phone one night in late November but is now thankful that he did. “On the other line was a transplant coordinator from…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.